Fly News Breaks for September 13, 2017
Sep 13, 2017 | 07:31 EDT
Needham analyst Alan Carr raised his price target on Biohaven as he is increasingly optimistic that a Phase 2/3 trial of the company's trigriluzole drug will yield positive data. He keeps a Buy rating on the stock.
News For BHVN From the Last 2 Days